ARWR Arrowhead Pharmaceuticals, Inc.: Business Value to Revenue

Public company logo of arrowheadpharma.com (ARWR)

Arrowhead Pharmaceuticals (ARWR) capitalization depends on the results of RNA therapy clinical trials and the rate of cash burn. The EV/Sales ratio demonstrates the market valuation of the business accounting for debt load, and the current value of 14148.66 captures the real-time level. Stable demand for liver disease treatments ensures sales resilience, while the company's environmental profile is limited to standard laboratory waste control.

Arrowhead Pharmaceuticals (ARWR): Company Value to Revenue from 11/23/2025 to 11/20/2026

arrowheadpharma.com - analytical breakdowns and key metrics (ARWR)

- company stock capitalization data:
Fundamental company valuation:ARWR - Arrowhead Pharmaceuticals
Product sample of Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals' specialization in innovative RNA therapeutics drives a high intellectual capital valuation, which the market tracks via the EV/Sales trajectory to exclude the impact of debt load. This ratio compares the total enterprise value to sales volume, allowing investors to assess the premium paid for future growth and capture the rate of market value correction amid inflationary pressures.